SlideShare a Scribd company logo
M E N I N G I T I S
P R E S E N T E D B Y
N U R U L H I D A Y U B I N T I I B R A H I M
N I K N O R L I Y A N A
OUTLINE
1. Introduction to meningitis
2. Risk factor
3. Anatomy and prognosis
4. Aetiology
5. History and physical examination
6. Clinical features
7. Complications
8. Differential diagnosis
9. Investigations
10. Management
INTRODUCTION
 Meningitis is a disease caused by the inflammation of the meninges.
 The inflammation is usually caused by an infection of the fluid surrounding the
brain and spinal cord.
 It can be life-threatening because of the inflammation’s proximity to the brain
and spinal cord; therefore the condition is classified as a medical emergency.
 If not treated, meningitis can lead to brain swelling and cause permanent
disability, coma, and even death.
 Broadly classified as :
I. Acute meningitis
II. Chronic meningitis
WHAT IS MENINGITIS?
TERMS
Set of symptoms similar to those of meningitis but not caused by meningitis.
 Meningism is caused by non-meningitic irritation of the meninges, usually associated
with acute febrile illness, especially in children and adolescents.
 It therefore requires differentiating from other CNS problems with similar symptoms,
including meningitis and some types of intracranial hemorrhage.
 The severity of clinical features varies with the causative organism.
M E N I N G I S M
RISK FACTORS
Risk factors that place people at higher risk for bacterial meningitis include
the following:
 Adults older than 60 years of age
 Children younger than 5 years of age
 People with alcoholism
 People with sickle cell anemia
 People with cancer, especially those receiving chemotherapy
 People who have received transplants and are taking drugs that suppress
the immune system
 People with diabetes
 Those recently exposed to meningitis at home
 People living in close quarters (military barracks, dormitories)
 IV drug users
 People with shunts in place for hydrocephalus
ANATOMY OF MENINGES
The meninges is the system of the membranes which envelops
the CNS. It has 3 layers:
1. Dura mater
2. Arachnoid mater
3. Pia mater
Subarachnoid space – is the space which is filled with CSF
ANATOMY OF MENINGES
ANATOMY OF MENINGES
ANATOMY OF MENINGES
TRANSMISSION
H O W D O E S M E N I N G I T I S S P R E A D ?
An infectious agent can gain access to the CNS and cause meningeal disease via any of
the 3 following major pathways:
Direct contiguous spread (e.g. sinusitis, otitis media, congenital malformations, trauma,
or direct inoculation during intracranial manipulation)
1 . I N V A S I O N O F T H E B L O O D S T R E A M
Invasion of the bloodstream (i.e., bacteremia, viremia, fungemia, or parasitemia) and
subsequent hematogenous seeding of the CNS
2 . R E T R O G R A D E N E U R O N A L PAT H W AY
A retrograde neuronal (eg, olfactory and peripheral nerves) pathway (eg, Naegleria
fowleri or Gnathostoma spinigerum)
3 . D I R E C T C O N T I G U O U S S P R E A D
TRANSMISSION
H O W D O E S M E N I N G I T I S S P R E A D ?
3 . D I R E C T C O N T I G U O U S S P R E A D
 Local extension from contiguous extracerebral infection (eg, otitis media,
mastoiditis, or sinusitis) is a common cause.
 Possible pathways for the migration of pathogens from the middle ear to the
meninges include the following:
1. The bloodstream
2. Preformed tissue planes (eg, posterior fossa)
3. Temporal bone fractures
4. The oval or round window membranes of the labyrinths
PATHOGENESIS
PATHOGENESIS
PROGNOSIS
Patients with meningitis who present with an impaired level of
consciousness are at increased risk for neurologic sequelae or death.
A seizure during an episode of meningitis also is a risk factor for mortality
or neurologic sequelae, particularly if the seizure is prolonged or difficult
to control.
In bacterial meningitis, several risk factors are associated with death and
with neurologic disability. A risk score has been derived and validated in
adults with bacterial meningitis. This score includes the following
variables, which are associated with an adverse clinical outcome:
1. Older age
2. Increased heart rate
3. Lower Glasgow Coma Scale score
4. Cranial nerve palsies
5. CSF leukocyte count lower than 1000/μL
6. Gram-positive cocci on CSF Gram stain
PROGNOSIS
 Advanced bacterial meningitis can lead to brain damage,
coma, and death.
 In 50% of patients, several complications may develop in the
days to weeks following infection.
 Long-term sequelae are seen in as many as 30% of survivors
and vary with etiologic agent, patient age, presenting
features, and hospital course. Patients usually have subtle CNS
changes.
AETIOLOGY
B A C T E R I A L
V I R A L
F U N G A L
P H Y S I C A L I N J U R Y
D R U G S R E A C T I O N
Severity/ treatment of illness differ depending on the cause. Thus, it is
important to know the specific cause of meningitis.
AETIOLOGY
B A C T E R I A L M E N I N G I T I S V I R A L M E N I N G I T I S
 The most serious form of meningitis is
bacterial.
 Even with treatment, bacterial meningitis
can be fatal some of the time.
 If bacterial meningitis progresses rapidly,
in 24 hours or less, death may occur in
more than half of those who develop it,
even with proper medical treatment.
 Determining how many people get viral
meningitis is difficult because it often
remains undiagnosed and is easily
confused with the flu.
 The prognosis for viral meningitis is much
better than that for bacterial meningitis,
with most people recovering completely
with simple treatment of the symptoms.
AETIOLOGY
F U N G A L M E N I N G I T I S A S E P T I C M E N I N G I T I S
 Fungal meningitis is a serious form of
meningitis that is normally limited to
people with impaired immune systems.
 Aseptic meningitis is a term referring to
the broad category of meningitis that is
not caused by bacteria.
 Approximately 50% of aseptic meningitis
is due to viral infections.
 Other less common causes include drug
reactions or allergies, and inflammatory
diseases like lupus.
 It occurs in individuals of all ages but is
more common in children
BACTERIAL CAUSES
 Listeria monocytogenes ( >50 years old)
 Group A β-hemolytic streptococcus
 Group B β-hemolytic streptococcus
 Mycoplasma pneumoniae
 Gram –ve rods
C O M M O N O R G A N I S M S :
1. Streptococcus pneumoniae (α-hemolytic streptococcus)
2. Neisseria meningitidis
3. Haemophilus influenzae
O T H E R O R G A N I S M S :
V I R A L C A U S E S
 Enteroviruses
 Herpes simplex virus
ORGANISMS
R I S K O R P R E D I S P O S I N G F A C T O R S B A C T E R I A L P A T H O G E N
Age 3 months – 18 years
 Neisseria meningitidis
 Streptococcus penumoniae
 Haemophilus influenza
Age 18 – 50 years
 Streptococcus penumoniae
 Neisseria meningitidis
 Haemophilus influenza
Age > 50 years
 Streptococcus penumoniae
 Neisseria meningitidis
 Listeria monocytogenes
 Aerobic gram-negative bacilli
Immunocompromised state
 Streptococcus penumoniae
 Neisseria meningitidis
 Listeria monocytogenes
 Aerobic gram-negative bacilli
Intracranial manipulation, including neurosurgery
 Staphylococcus aureus
 Coagulase negative staphylococci
 Aerobic gram-negative bacilli, including
Pseudomonas aeruginosa
Basilar skull fracture
 Streptococcus penumoniae
 Haemophilus influenza
 Group A streptococci
NEISSERIA MENINGITIDIS
 Also known as meningococcal meningitis
 Gram negative aerobic cocci, capsule
 10% of healthy people are healthy nasopharyngeal
carriers
 Begin as throat infection, rash
 Vaccination is recommended
NEISSERIA MENINGITIDIS
STREPTOCOCCUS PNEUMONIAE
 Gram positive diplococci
 70% of people are healthy nasopharyngeal carriers
 Most common in children (1 month to 4 years)
 Mortality: 30% in children, 80% in elderly
 Prevented by vaccination
NEISSERIA MENINGITIDIS
HISTORY TAKING
 ~25% of those who develop meningitis have symptoms that develop
over 24 hours. The remainder generally become ill over one to seven
days.
 ~25% of patients have concomitant sinusitis or otitis that could
predispose to S pneumoniae meningitis.
 Occasionally, if someone has been on antibiotics for another infection,
the symptoms can take longer to develop or may be less intense.
 If someone is developing fungal meningitis (most commonly someone
who is HIV positive), the symptoms may take weeks to develop.
D U R AT I O N
NEISSERIA MENINGITIDIS
HISTORY TAKING
 In contrast, patients with subacute bacterial meningitis and most
patients with viral meningitis present with neurologic symptoms
developing over 1 – 7 days.
 Chronic symptoms lasting longer than 1 week suggest the presence of
meningitis caused by certain viruses or by tuberculosis, syphilis, fungi
(especially cryptococci), or carcinomatosis.
D U R AT I O N
NEISSERIA MENINGITIDIS
HISTORY TAKING
NEISSERIA MENINGITIDIS
HISTORY TAKING
S Y M P T O M S I G N M E C H A N I S M
Chills, rigors Fever (T>38°) Endogenous cytokines (released during the
immune response to the invading
pathogens) affect the thermoregulatory
neurons of the hypothalamus, changing the
central regulation of body temperature.
Invading viruses or bacteria produce
exogenous substances (pyrogens) that can
also re-set the hypothalamic thermal set
point.
Nuchal rigidity (neck stiffness) Brudzinski sign and Kernig sign Flexion of the spine leads to stretching of
the meninges.
In meningitis, traction on the inflamed
meninges is painful, resulting in limited
range of motion through the spine
(especially in the cervical spine).
Altered mental status Decreased Glasgow Coma Scale (GCS) ↑ ICP → brain herniation → damage to
the reticular formation (structure in the
brainstem that governs consciousness)
NEISSERIA MENINGITIDIS
HISTORY TAKING
S Y M P T O M S I G N M E C H A N I S M
Focal neurological deficits, e.g. vision loss Examples: cranial nerve palsies,
hemiparesis, hypertonia, nystagmus
Cytotoxic edema and ↑ ICP lead to
neuronal damage.
Signs or symptoms depend on the affected
area (cerebrum, cerebellum, brainstem,
etc.)
Seizures Inflammation in the brain alters membrane
permeability, lowering the seizure
threshold. Exact seizure pathophysiology is
unknown.
Headache Jolt accentuation of headache: headache
worse when patient vigorously shakes head
Bacterial exotoxins, cytokines, and ↑ ICP
stimulate nociceptors in the meninges
(cerebral tissue itself lacks nerve endings
that generate pain sensation).
Photophobia Due to meningeal irritation. Mechanisms
unclear; pathways are thought to involve
the trigeminal nerve.
Nausea and vomiting ↑ ICP stimulates the area
postrema (vomiting centre), causing nausea
and vomiting.
Petechial rash Meningococcemia (due to N. meningitidis)
NEISSERIA MENINGITIDIS
HISTORY TAKING
O T H E R I M P O R TA N T H I S T O R Y
 Contact with TB patient (TB meningitis)
 Infection of middle ear, sinuses, lung or tooth and gum (brain abscess)
 Contact with infected bodily secretions (meningitis, herpes encephalitis)
 Sexual contact with a person infected with HIV (HIV encephalopathy)
 Penetrating head trauma (brain abscess)
 Neurosurgical complications (meningitis, brain abscess)
 A chronic illness, such as cancer
 A weakened immune system, such those with alcoholism, diabetes, HIV or people
who have had organ transplant.
 A history of recent antibiotic use should be elicited. 40% of patients who present
with acute or subacute bacterial meningitis have previously been treated with oral
antibiotics (presumably because of misdiagnosis at the time of initial presentation).
NEISSERIA MENINGITIDIS
PHYSICAL EXAMINATION
G E N E R A L E X A M I N AT I O N
 Non-toxic looking might suggestive of viral origin.
 Sick, toxic looking might suggest bacterial origin.
 Glasgow-coma scale
 Kernig’s sign
 Brudzinki’s sign
 Look for other source of infections:
 Cutaneous petachie/purpura rash  meningococcus
 Middle ear, sinus infection
 Pneumonia  pneumococcus
 Papilledema (increase ICP)
 Cranial nerves examination (III, IV, V, VI, and VII)
S P E C I F I C E X A M I N AT I O N
NEISSERIA MENINGITIDIS
PHYSICAL EXAMINATION
K E R N I G ’ S S I G N ( M E N I N G E A L S T R E T C H T E S T )
NEISSERIA MENINGITIDIS
PHYSICAL EXAMINATION
B R U D Z I N S K I ’ S S I G N ( M E N I N G E A L S T R E T C H T E S T )
NEISSERIA MENINGITIDIS
CLINICAL FEATURES
C H R O N I C M E N I N G I T I S
 Lymphadenopathy
 Papilledema and tuberculomas during funduscopy
 Meningismus
 Cranial nerve palsies
 Occurs most common shortly after primary infection in childhood or as part of
military TB.
 The presentation of chronic tuberculous meningitis may be acute, but the classic
presentation is subacute and spans weeks. Patients generally have a prodrome
consisting of fever of varying degrees, malaise, and intermittent headaches.
T U B E R C U L O U S M E N I N G I T I S
NEISSERIA MENINGITIDIS
CLINICAL FEATURES
Cranial nerve palsies (III, IV, V, VI, and VII) often develop, suggesting basilar
meningeal involvement.
Clinical staging of tuberculous meningitis is based on neurologic status, as
follows:
 Stage 1 - No change in mental function, with no deficits and no
hydrocephalus
 Stage 2 - Confusion and evidence of neurologic deficit
 Stage 3 - Stupor and lethargy
T U B E R C U L O U S M E N I N G I T I S
C L I N I C A L S TA G I N G O F T U B E R C U L O U S M E N I N G I T I S
NEISSERIA MENINGITIDIS
CLINICAL FEATURES
NEISSERIA MENINGITIDIS
COMPLICATIONS
1 . H E A R I N G L O S S
2 . C E R E B R A L O E D E M A A N D I N C R E A S E D I C P
4 . B R A I N A B S C E S S
4 . S T R O K E
Infections / inflammation from subarachnoid space  via cochlear aqueduct  inner ear
 Inflammatory response – damages cochlear (hair cells)
Cerebral edema may be vasogenic, from increased vascular permeability, cytotoxic from cerebral hypoxia, interstitial, from
increased CSF volume, or a combination of all. Increased intracranial pressure, in turn, causes decreased cerebral perfusion,
hypoxia/ischemia, and neuronal necrosis.
3 . D I S S E M I N AT E D I N T R A V A S C U L A R C O A G U L O PAT H Y ( D I C )
Bacterial products can damage the brain and blood vessels directly. Bacterial toxins cause neuronal apoptosis, and cell wall
lipopolysaccharide (endotoxin), released from bacteria, activates clotting causing disseminated intravascular coagulation (DIC).
NEISSERIA MENINGITIDIS
DIFFERENTIAL DIAGNOSIS
1 . S u b a r a c h n o i d h e m o r r h a g e
2 . T B m e n i n g i t i s
3 . S p a c e - o c c u p y i n g l e s i o n
4 . M e n i n g o e n c a p h a l i t i s
5 . E p i l e p s y
NEISSERIA MENINGITIDIS
INVESTIGATIONS
B L O O D T E S T S
1. Full blood count ( white cell count)
2. C-reactive protein
3. Blood culture and sensitivity
L U M B A R P U N C T U R E A N D C S F A N A LY S I S
For definitive diagnosis of meningitis, CSF needs to be collected for analysis.
C O N T R A I N D I C AT I O N S
 Infected skin over needle entry site
 Suspicion of increase ICP
 Coagulopathy
 Significant cardiorespiratory compromise
 Immunocompromised
NEISSERIA MENINGITIDIS
INVESTIGATIONS
L U M B A R P U N C T U R E A N D C S F A N A LY S I S
T E S T B A C T E R I A L V I R A L F U N G A L T U B E R C U L A R
Opening pressure Elevated Normal Variable Variable
WBC count >1,000 / mm3 <100/mm3 Variable Variable
Cell differential Neutrophils Lymphocytes Lymphocytes Lymphocytes
Protein Mild to marked
elevation
Normal or mildly
elevated
Elevated Very high
CSF-to-serum
glucose ratio
Markedly decreased normal Low Low
I M A G I N G
If a patient has the following:
Focal neurologic findings (excluding cranial nerve palsies), new-onset seizures, severely immunocompromised
state, papilledema or presents with coma, perform a head computed tomography scan prior to doing a lumbar
puncture to rule out the presence of intracranial mass lesions because of the potential risk for herniation
NEISSERIA MENINGITIDIS
MANAGEMENT
S U P P O R T I V E T R E AT M E N T
Airway, breathing and circulation
 Mechanical ventilation – level of consciousness is very low / evidence of respiratory failure
 Intravenous fluid therapy – if hypotension or shock are present
Monitor vital signs and neurologic status regularly
Maintain adequate hydration and nutrition – tube feeding may be necessary
D E F I N I T I V E T R E AT M E N T ( P H A R M A C O T H E R PA P Y )
1. Antibiotic therapy
2. Anti-inflammatory therapy
3. Agents to decrease intracranial pressure (ICP)
4. Anti-convulsants
NEISSERIA MENINGITIDIS
MANAGEMENT
A N T I B I O T I C S ( A C U T E M E N I N G I T I S )
I N F E C T I O N
S U G G E S T E D T R E A T M E N T
C O M M E N T S
P R E F E R R E D A L T E R N A T I V E
Common organisms:
 Streptococcus
pneumoniae
 Neisseria meningitidis
 Haemophilus influenzae
Ceftriaxone 2gm IV q12h
OR
Cefotaxime 2 – 4gm IV q8h
Dexamethasone 10mg IV q6h
is recommended to be
administered 15 to 20 minutes
before or at the time of first
dose of antibiotics, for up to 4
days or until there is no
evidence of pneumococcal
meningitis.
Antibiotic treatment must be
started immediately,
regardless of any
investigations undertaken. If
no organism isolated and
patient is responding,
continue antibiotics for 14
days.
NEISSERIA MENINGITIDIS
MANAGEMENT
A N T I B I O T I C S ( A C U T E M E N I N G I T I S )
I S O L A T E D C A U S A T I V E
O R G A N I S M
S U G G E S T E D T R E A T M E N T
C O M M E N T S
P R E F E R R E D A L T E R N A T I V E
HAEMOPHILUS INFUENZAE
(GRAM –VE BACILLI)
Ceftriaxone 2gm IV q12h
STREPTOCOCCUS PNEUMONIAE
(GRAM +VE COCCI)
Benzylpenicillin 4MU IV q4-
6h for 10-14 days.
For penicillin resistant strains
Vancomycin 1gm IV q12h
NEISSERIA MENINGITIDIS
(GRAM –VE COCCI)
Prophylaxis for household and
close contact of meningococcal
meningitis
Ceftriaxone 2gm IV q12h
Ciprofloxacin 500mg PO as
single dose;
Close contacts are defined as
those individuals who have
had contact with
oropharyngeal secretions
either through kissing or by
sharing toys, beverages, or
cigarettes.
NEISSERIA MENINGITIDIS
MANAGEMENT
A N T I B I O T I C S ( C H R O N I C M E N I N G I T I S )
I N F E C T I O N
S U G G E S T E D T R E A T M E N T
C O M M E N T S
P R E F E R R E D A L T E R N A T I V E
TUBERCULOUS MENINGITIS
Mycobacterium tuberculosis
Intensive 2 months S/EHRZ
and 10 months HR
Pyridoxine 10- 50mg PO q24h
needs to be prescribed
together with Isoniazid.
(Streptomycin should replace
Ethambutol in TB meningitis
as it crosses BBB better than
Ethambutol.)
Treatment is continued for 12
months.
CPG on management of
Tuberculosis, 3rd edition,
2012; 16, 22, 40-42, 56)
WHO Treatment of
Tuberculosis Guidelines, 4th
ed. 2009
NEISSERIA MENINGITIDIS
MANAGEMENT
A N T I - I N F L A M M AT O R Y T H E R A P Y
Dexamethasone 10 mg IV 6 hourly x 4 days
Mannitol 1 – 1.5 g/kg IV given over 15 minutes
I C P L O W E R I N G A G E N T
A N T I C O N V U L S A N T S
Diazepam, Lorazepam
Administered if patient has seizure
Action:
Mannitol is a hyperosmolar agent that makes the intravascular space hyperosmolar to the brain and permits movement of water
from brain tissue into the intravascular compartment
NEISSERIA MENINGITIDIS
PREVENTION AND PROPHYLAXIS
P R E C A U T I O N
Completion of recommended schedule of vaccination is an effective way of protecting individuals from certain
types of bacterial meningitis (E.g. meningococcus, pneumococcus and Hib)
F O L L O W U P
 Repeat cerebrospinal fluid exam in patients in whom there is doubt about the success of therapy or the
accuracy of the initial diagnosis
 Patients who respond promptly to therapy may no longer need repeat cerebrospinal fluid exams
 Monitor for hydrocephalus and treat the condition appropriately - hydrocephalus usually manifests within the
first few weeks of infection and is treated with ventriculoperitoneal shunting
 Monitor for neurologic sequelae and provide appropriate supportive therapy
 Sequelae include hearing impairment, cranial nerve palsies and motor deficits
 Supportive therapy should be individually tailored
Use of mask, gloves, and gowns prevents spread of disease as meningitis is a droplet infection
V A C C I N AT I O N
THANK YOU

More Related Content

Similar to 17managementofmeningitis-181226083242.pdf

Meningitis
MeningitisMeningitis
Meningitis
Dr Arathy R Nath
 
Meningitis
MeningitisMeningitis
Meningitis
Raied Mansour
 
Meningitis In Children
Meningitis  In ChildrenMeningitis  In Children
Meningitis In Children
Dr Harim Mohsin
 
Bacterial meningitis
Bacterial meningitis Bacterial meningitis
Bacterial meningitis
Abigail Abalos
 
GROUP NO 1 PPT.pptx
GROUP NO 1 PPT.pptxGROUP NO 1 PPT.pptx
GROUP NO 1 PPT.pptx
ShumailaQadir2
 
Meningitis 2012
Meningitis 2012Meningitis 2012
Meningitis 2012
Felipe Arias
 
MENINGITIS & ENCEPHALITIS - Ayushi.pptx pdf
MENINGITIS & ENCEPHALITIS - Ayushi.pptx pdfMENINGITIS & ENCEPHALITIS - Ayushi.pptx pdf
MENINGITIS & ENCEPHALITIS - Ayushi.pptx pdf
AditiShah380128
 
Meningitis
MeningitisMeningitis
Meningitis
Ekta Patel
 
Meningitis.pptx
Meningitis.pptxMeningitis.pptx
Meningitis.pptx
SumalkaSarathchandra
 
CNS infections
CNS infectionsCNS infections
Cns infections
Cns infectionsCns infections
Cns infections
LetaJarso
 
BACTERIAL MENINGITIS present today.pptx
BACTERIAL MENINGITIS present today.pptxBACTERIAL MENINGITIS present today.pptx
BACTERIAL MENINGITIS present today.pptx
HajaSovula2
 
CNS Infections Siddiqui
CNS Infections SiddiquiCNS Infections Siddiqui
CNS Infections Siddiqui
tjsiddiqui
 
Infections and salivary gland disease in pediatric age: how to manage - Slide...
Infections and salivary gland disease in pediatric age: how to manage - Slide...Infections and salivary gland disease in pediatric age: how to manage - Slide...
Infections and salivary gland disease in pediatric age: how to manage - Slide...
WAidid
 
Pyogenic infection
Pyogenic infectionPyogenic infection
Pyogenic infection
Sayali Gujjewar
 
#StaySafe: Alert Points for Meningococcal Meningitis
#StaySafe: Alert Points for Meningococcal Meningitis#StaySafe: Alert Points for Meningococcal Meningitis
#StaySafe: Alert Points for Meningococcal Meningitis
EpidAlert Informative Initiative
 
CNS infections.pptx
CNS infections.pptxCNS infections.pptx
CNS infections.pptx
MusFa1
 
Cns
CnsCns
Infections of the central nervous and locomotor systems
Infections of the central nervous and locomotor systemsInfections of the central nervous and locomotor systems
Infections of the central nervous and locomotor systems
Saeed Bajafar
 
MENINGITIS.pptx hbhbbhnsdvjjjhhvdssxvhuhhhh
MENINGITIS.pptx hbhbbhnsdvjjjhhvdssxvhuhhhhMENINGITIS.pptx hbhbbhnsdvjjjhhvdssxvhuhhhh
MENINGITIS.pptx hbhbbhnsdvjjjhhvdssxvhuhhhh
epicsoundever
 

Similar to 17managementofmeningitis-181226083242.pdf (20)

Meningitis
MeningitisMeningitis
Meningitis
 
Meningitis
MeningitisMeningitis
Meningitis
 
Meningitis In Children
Meningitis  In ChildrenMeningitis  In Children
Meningitis In Children
 
Bacterial meningitis
Bacterial meningitis Bacterial meningitis
Bacterial meningitis
 
GROUP NO 1 PPT.pptx
GROUP NO 1 PPT.pptxGROUP NO 1 PPT.pptx
GROUP NO 1 PPT.pptx
 
Meningitis 2012
Meningitis 2012Meningitis 2012
Meningitis 2012
 
MENINGITIS & ENCEPHALITIS - Ayushi.pptx pdf
MENINGITIS & ENCEPHALITIS - Ayushi.pptx pdfMENINGITIS & ENCEPHALITIS - Ayushi.pptx pdf
MENINGITIS & ENCEPHALITIS - Ayushi.pptx pdf
 
Meningitis
MeningitisMeningitis
Meningitis
 
Meningitis.pptx
Meningitis.pptxMeningitis.pptx
Meningitis.pptx
 
CNS infections
CNS infectionsCNS infections
CNS infections
 
Cns infections
Cns infectionsCns infections
Cns infections
 
BACTERIAL MENINGITIS present today.pptx
BACTERIAL MENINGITIS present today.pptxBACTERIAL MENINGITIS present today.pptx
BACTERIAL MENINGITIS present today.pptx
 
CNS Infections Siddiqui
CNS Infections SiddiquiCNS Infections Siddiqui
CNS Infections Siddiqui
 
Infections and salivary gland disease in pediatric age: how to manage - Slide...
Infections and salivary gland disease in pediatric age: how to manage - Slide...Infections and salivary gland disease in pediatric age: how to manage - Slide...
Infections and salivary gland disease in pediatric age: how to manage - Slide...
 
Pyogenic infection
Pyogenic infectionPyogenic infection
Pyogenic infection
 
#StaySafe: Alert Points for Meningococcal Meningitis
#StaySafe: Alert Points for Meningococcal Meningitis#StaySafe: Alert Points for Meningococcal Meningitis
#StaySafe: Alert Points for Meningococcal Meningitis
 
CNS infections.pptx
CNS infections.pptxCNS infections.pptx
CNS infections.pptx
 
Cns
CnsCns
Cns
 
Infections of the central nervous and locomotor systems
Infections of the central nervous and locomotor systemsInfections of the central nervous and locomotor systems
Infections of the central nervous and locomotor systems
 
MENINGITIS.pptx hbhbbhnsdvjjjhhvdssxvhuhhhh
MENINGITIS.pptx hbhbbhnsdvjjjhhvdssxvhuhhhhMENINGITIS.pptx hbhbbhnsdvjjjhhvdssxvhuhhhh
MENINGITIS.pptx hbhbbhnsdvjjjhhvdssxvhuhhhh
 

Recently uploaded

DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
Dr Rachana Gujar
 
2024 HIPAA Compliance Training Guide to the Compliance Officers
2024 HIPAA Compliance Training Guide to the Compliance Officers2024 HIPAA Compliance Training Guide to the Compliance Officers
2024 HIPAA Compliance Training Guide to the Compliance Officers
Conference Panel
 
GIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure andGIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure and
MuzafarBohio
 
Unlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdfUnlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdf
Lift Ability
 
The Power of Superfoods and Exercise.pdf
The Power of Superfoods and Exercise.pdfThe Power of Superfoods and Exercise.pdf
The Power of Superfoods and Exercise.pdf
Dr Rachana Gujar
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
priyabhojwani1200
 
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdfComprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Dr Rachana Gujar
 
Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured ApproachBringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
Brian Frerichs
 
chatgptfornlp-230314021506-2f03f614.pdf. 21506-2f03f614.pdf
chatgptfornlp-230314021506-2f03f614.pdf. 21506-2f03f614.pdfchatgptfornlp-230314021506-2f03f614.pdf. 21506-2f03f614.pdf
chatgptfornlp-230314021506-2f03f614.pdf. 21506-2f03f614.pdf
marynayjun112024
 
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
bkling
 
CANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' CaregiversCANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' Caregivers
CANSA The Cancer Association of South Africa
 
National Rural Health Mission(NRHM).pptx
National Rural Health Mission(NRHM).pptxNational Rural Health Mission(NRHM).pptx
National Rural Health Mission(NRHM).pptx
Jyoti Chand
 
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
rightmanforbloodline
 
DRAFT Ventilator Rapid Reference version 2.4.pdf
DRAFT Ventilator Rapid Reference  version  2.4.pdfDRAFT Ventilator Rapid Reference  version  2.4.pdf
DRAFT Ventilator Rapid Reference version 2.4.pdf
Robert Cole
 
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Levi Shapiro
 
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...
Ear Solutions (ESPL)
 
Luxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage CenterLuxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage Center
Chandrima Spa Ajman
 
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Lighthouse Retreat
 
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdfMBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
bkling
 
NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022
nktiacc3
 

Recently uploaded (20)

DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdfDECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
DECODING THE RISKS - ALCOHOL, TOBACCO & DRUGS.pdf
 
2024 HIPAA Compliance Training Guide to the Compliance Officers
2024 HIPAA Compliance Training Guide to the Compliance Officers2024 HIPAA Compliance Training Guide to the Compliance Officers
2024 HIPAA Compliance Training Guide to the Compliance Officers
 
GIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure andGIT BS.pptx about human body their structure and
GIT BS.pptx about human body their structure and
 
Unlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdfUnlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdf
 
The Power of Superfoods and Exercise.pdf
The Power of Superfoods and Exercise.pdfThe Power of Superfoods and Exercise.pdf
The Power of Superfoods and Exercise.pdf
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
 
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdfComprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
Comprehensive Rainy Season Advisory: Safety and Preparedness Tips.pdf
 
Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured ApproachBringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
 
chatgptfornlp-230314021506-2f03f614.pdf. 21506-2f03f614.pdf
chatgptfornlp-230314021506-2f03f614.pdf. 21506-2f03f614.pdfchatgptfornlp-230314021506-2f03f614.pdf. 21506-2f03f614.pdf
chatgptfornlp-230314021506-2f03f614.pdf. 21506-2f03f614.pdf
 
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
Let's Talk About It: Breast Cancer (What is Mindset and Does it Really Matter?)
 
CANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' CaregiversCANSA support - Caring for Cancer Patients' Caregivers
CANSA support - Caring for Cancer Patients' Caregivers
 
National Rural Health Mission(NRHM).pptx
National Rural Health Mission(NRHM).pptxNational Rural Health Mission(NRHM).pptx
National Rural Health Mission(NRHM).pptx
 
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
 
DRAFT Ventilator Rapid Reference version 2.4.pdf
DRAFT Ventilator Rapid Reference  version  2.4.pdfDRAFT Ventilator Rapid Reference  version  2.4.pdf
DRAFT Ventilator Rapid Reference version 2.4.pdf
 
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
 
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...
Exploring the Benefits of Binaural Hearing: Why Two Hearing Aids Are Better T...
 
Luxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage CenterLuxurious Spa In Ajman Chandrima Massage Center
Luxurious Spa In Ajman Chandrima Massage Center
 
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
Psychedelic Retreat Portugal - Escape to Lighthouse Retreats for an unforgett...
 
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdfMBC Support Group for Black Women – Insights in Genetic Testing.pdf
MBC Support Group for Black Women – Insights in Genetic Testing.pdf
 
NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022
 

17managementofmeningitis-181226083242.pdf

  • 1. M E N I N G I T I S P R E S E N T E D B Y N U R U L H I D A Y U B I N T I I B R A H I M N I K N O R L I Y A N A
  • 2. OUTLINE 1. Introduction to meningitis 2. Risk factor 3. Anatomy and prognosis 4. Aetiology 5. History and physical examination 6. Clinical features 7. Complications 8. Differential diagnosis 9. Investigations 10. Management
  • 3. INTRODUCTION  Meningitis is a disease caused by the inflammation of the meninges.  The inflammation is usually caused by an infection of the fluid surrounding the brain and spinal cord.  It can be life-threatening because of the inflammation’s proximity to the brain and spinal cord; therefore the condition is classified as a medical emergency.  If not treated, meningitis can lead to brain swelling and cause permanent disability, coma, and even death.  Broadly classified as : I. Acute meningitis II. Chronic meningitis WHAT IS MENINGITIS?
  • 4. TERMS Set of symptoms similar to those of meningitis but not caused by meningitis.  Meningism is caused by non-meningitic irritation of the meninges, usually associated with acute febrile illness, especially in children and adolescents.  It therefore requires differentiating from other CNS problems with similar symptoms, including meningitis and some types of intracranial hemorrhage.  The severity of clinical features varies with the causative organism. M E N I N G I S M
  • 5. RISK FACTORS Risk factors that place people at higher risk for bacterial meningitis include the following:  Adults older than 60 years of age  Children younger than 5 years of age  People with alcoholism  People with sickle cell anemia  People with cancer, especially those receiving chemotherapy  People who have received transplants and are taking drugs that suppress the immune system  People with diabetes  Those recently exposed to meningitis at home  People living in close quarters (military barracks, dormitories)  IV drug users  People with shunts in place for hydrocephalus
  • 6. ANATOMY OF MENINGES The meninges is the system of the membranes which envelops the CNS. It has 3 layers: 1. Dura mater 2. Arachnoid mater 3. Pia mater Subarachnoid space – is the space which is filled with CSF
  • 10. TRANSMISSION H O W D O E S M E N I N G I T I S S P R E A D ? An infectious agent can gain access to the CNS and cause meningeal disease via any of the 3 following major pathways: Direct contiguous spread (e.g. sinusitis, otitis media, congenital malformations, trauma, or direct inoculation during intracranial manipulation) 1 . I N V A S I O N O F T H E B L O O D S T R E A M Invasion of the bloodstream (i.e., bacteremia, viremia, fungemia, or parasitemia) and subsequent hematogenous seeding of the CNS 2 . R E T R O G R A D E N E U R O N A L PAT H W AY A retrograde neuronal (eg, olfactory and peripheral nerves) pathway (eg, Naegleria fowleri or Gnathostoma spinigerum) 3 . D I R E C T C O N T I G U O U S S P R E A D
  • 11. TRANSMISSION H O W D O E S M E N I N G I T I S S P R E A D ? 3 . D I R E C T C O N T I G U O U S S P R E A D  Local extension from contiguous extracerebral infection (eg, otitis media, mastoiditis, or sinusitis) is a common cause.  Possible pathways for the migration of pathogens from the middle ear to the meninges include the following: 1. The bloodstream 2. Preformed tissue planes (eg, posterior fossa) 3. Temporal bone fractures 4. The oval or round window membranes of the labyrinths
  • 14. PROGNOSIS Patients with meningitis who present with an impaired level of consciousness are at increased risk for neurologic sequelae or death. A seizure during an episode of meningitis also is a risk factor for mortality or neurologic sequelae, particularly if the seizure is prolonged or difficult to control. In bacterial meningitis, several risk factors are associated with death and with neurologic disability. A risk score has been derived and validated in adults with bacterial meningitis. This score includes the following variables, which are associated with an adverse clinical outcome: 1. Older age 2. Increased heart rate 3. Lower Glasgow Coma Scale score 4. Cranial nerve palsies 5. CSF leukocyte count lower than 1000/μL 6. Gram-positive cocci on CSF Gram stain
  • 15. PROGNOSIS  Advanced bacterial meningitis can lead to brain damage, coma, and death.  In 50% of patients, several complications may develop in the days to weeks following infection.  Long-term sequelae are seen in as many as 30% of survivors and vary with etiologic agent, patient age, presenting features, and hospital course. Patients usually have subtle CNS changes.
  • 16. AETIOLOGY B A C T E R I A L V I R A L F U N G A L P H Y S I C A L I N J U R Y D R U G S R E A C T I O N Severity/ treatment of illness differ depending on the cause. Thus, it is important to know the specific cause of meningitis.
  • 17. AETIOLOGY B A C T E R I A L M E N I N G I T I S V I R A L M E N I N G I T I S  The most serious form of meningitis is bacterial.  Even with treatment, bacterial meningitis can be fatal some of the time.  If bacterial meningitis progresses rapidly, in 24 hours or less, death may occur in more than half of those who develop it, even with proper medical treatment.  Determining how many people get viral meningitis is difficult because it often remains undiagnosed and is easily confused with the flu.  The prognosis for viral meningitis is much better than that for bacterial meningitis, with most people recovering completely with simple treatment of the symptoms.
  • 18. AETIOLOGY F U N G A L M E N I N G I T I S A S E P T I C M E N I N G I T I S  Fungal meningitis is a serious form of meningitis that is normally limited to people with impaired immune systems.  Aseptic meningitis is a term referring to the broad category of meningitis that is not caused by bacteria.  Approximately 50% of aseptic meningitis is due to viral infections.  Other less common causes include drug reactions or allergies, and inflammatory diseases like lupus.  It occurs in individuals of all ages but is more common in children
  • 19. BACTERIAL CAUSES  Listeria monocytogenes ( >50 years old)  Group A β-hemolytic streptococcus  Group B β-hemolytic streptococcus  Mycoplasma pneumoniae  Gram –ve rods C O M M O N O R G A N I S M S : 1. Streptococcus pneumoniae (α-hemolytic streptococcus) 2. Neisseria meningitidis 3. Haemophilus influenzae O T H E R O R G A N I S M S : V I R A L C A U S E S  Enteroviruses  Herpes simplex virus
  • 20. ORGANISMS R I S K O R P R E D I S P O S I N G F A C T O R S B A C T E R I A L P A T H O G E N Age 3 months – 18 years  Neisseria meningitidis  Streptococcus penumoniae  Haemophilus influenza Age 18 – 50 years  Streptococcus penumoniae  Neisseria meningitidis  Haemophilus influenza Age > 50 years  Streptococcus penumoniae  Neisseria meningitidis  Listeria monocytogenes  Aerobic gram-negative bacilli Immunocompromised state  Streptococcus penumoniae  Neisseria meningitidis  Listeria monocytogenes  Aerobic gram-negative bacilli Intracranial manipulation, including neurosurgery  Staphylococcus aureus  Coagulase negative staphylococci  Aerobic gram-negative bacilli, including Pseudomonas aeruginosa Basilar skull fracture  Streptococcus penumoniae  Haemophilus influenza  Group A streptococci
  • 21. NEISSERIA MENINGITIDIS  Also known as meningococcal meningitis  Gram negative aerobic cocci, capsule  10% of healthy people are healthy nasopharyngeal carriers  Begin as throat infection, rash  Vaccination is recommended
  • 22. NEISSERIA MENINGITIDIS STREPTOCOCCUS PNEUMONIAE  Gram positive diplococci  70% of people are healthy nasopharyngeal carriers  Most common in children (1 month to 4 years)  Mortality: 30% in children, 80% in elderly  Prevented by vaccination
  • 23. NEISSERIA MENINGITIDIS HISTORY TAKING  ~25% of those who develop meningitis have symptoms that develop over 24 hours. The remainder generally become ill over one to seven days.  ~25% of patients have concomitant sinusitis or otitis that could predispose to S pneumoniae meningitis.  Occasionally, if someone has been on antibiotics for another infection, the symptoms can take longer to develop or may be less intense.  If someone is developing fungal meningitis (most commonly someone who is HIV positive), the symptoms may take weeks to develop. D U R AT I O N
  • 24. NEISSERIA MENINGITIDIS HISTORY TAKING  In contrast, patients with subacute bacterial meningitis and most patients with viral meningitis present with neurologic symptoms developing over 1 – 7 days.  Chronic symptoms lasting longer than 1 week suggest the presence of meningitis caused by certain viruses or by tuberculosis, syphilis, fungi (especially cryptococci), or carcinomatosis. D U R AT I O N
  • 26. NEISSERIA MENINGITIDIS HISTORY TAKING S Y M P T O M S I G N M E C H A N I S M Chills, rigors Fever (T>38°) Endogenous cytokines (released during the immune response to the invading pathogens) affect the thermoregulatory neurons of the hypothalamus, changing the central regulation of body temperature. Invading viruses or bacteria produce exogenous substances (pyrogens) that can also re-set the hypothalamic thermal set point. Nuchal rigidity (neck stiffness) Brudzinski sign and Kernig sign Flexion of the spine leads to stretching of the meninges. In meningitis, traction on the inflamed meninges is painful, resulting in limited range of motion through the spine (especially in the cervical spine). Altered mental status Decreased Glasgow Coma Scale (GCS) ↑ ICP → brain herniation → damage to the reticular formation (structure in the brainstem that governs consciousness)
  • 27. NEISSERIA MENINGITIDIS HISTORY TAKING S Y M P T O M S I G N M E C H A N I S M Focal neurological deficits, e.g. vision loss Examples: cranial nerve palsies, hemiparesis, hypertonia, nystagmus Cytotoxic edema and ↑ ICP lead to neuronal damage. Signs or symptoms depend on the affected area (cerebrum, cerebellum, brainstem, etc.) Seizures Inflammation in the brain alters membrane permeability, lowering the seizure threshold. Exact seizure pathophysiology is unknown. Headache Jolt accentuation of headache: headache worse when patient vigorously shakes head Bacterial exotoxins, cytokines, and ↑ ICP stimulate nociceptors in the meninges (cerebral tissue itself lacks nerve endings that generate pain sensation). Photophobia Due to meningeal irritation. Mechanisms unclear; pathways are thought to involve the trigeminal nerve. Nausea and vomiting ↑ ICP stimulates the area postrema (vomiting centre), causing nausea and vomiting. Petechial rash Meningococcemia (due to N. meningitidis)
  • 28. NEISSERIA MENINGITIDIS HISTORY TAKING O T H E R I M P O R TA N T H I S T O R Y  Contact with TB patient (TB meningitis)  Infection of middle ear, sinuses, lung or tooth and gum (brain abscess)  Contact with infected bodily secretions (meningitis, herpes encephalitis)  Sexual contact with a person infected with HIV (HIV encephalopathy)  Penetrating head trauma (brain abscess)  Neurosurgical complications (meningitis, brain abscess)  A chronic illness, such as cancer  A weakened immune system, such those with alcoholism, diabetes, HIV or people who have had organ transplant.  A history of recent antibiotic use should be elicited. 40% of patients who present with acute or subacute bacterial meningitis have previously been treated with oral antibiotics (presumably because of misdiagnosis at the time of initial presentation).
  • 29. NEISSERIA MENINGITIDIS PHYSICAL EXAMINATION G E N E R A L E X A M I N AT I O N  Non-toxic looking might suggestive of viral origin.  Sick, toxic looking might suggest bacterial origin.  Glasgow-coma scale  Kernig’s sign  Brudzinki’s sign  Look for other source of infections:  Cutaneous petachie/purpura rash  meningococcus  Middle ear, sinus infection  Pneumonia  pneumococcus  Papilledema (increase ICP)  Cranial nerves examination (III, IV, V, VI, and VII) S P E C I F I C E X A M I N AT I O N
  • 30. NEISSERIA MENINGITIDIS PHYSICAL EXAMINATION K E R N I G ’ S S I G N ( M E N I N G E A L S T R E T C H T E S T )
  • 31. NEISSERIA MENINGITIDIS PHYSICAL EXAMINATION B R U D Z I N S K I ’ S S I G N ( M E N I N G E A L S T R E T C H T E S T )
  • 32. NEISSERIA MENINGITIDIS CLINICAL FEATURES C H R O N I C M E N I N G I T I S  Lymphadenopathy  Papilledema and tuberculomas during funduscopy  Meningismus  Cranial nerve palsies  Occurs most common shortly after primary infection in childhood or as part of military TB.  The presentation of chronic tuberculous meningitis may be acute, but the classic presentation is subacute and spans weeks. Patients generally have a prodrome consisting of fever of varying degrees, malaise, and intermittent headaches. T U B E R C U L O U S M E N I N G I T I S
  • 33. NEISSERIA MENINGITIDIS CLINICAL FEATURES Cranial nerve palsies (III, IV, V, VI, and VII) often develop, suggesting basilar meningeal involvement. Clinical staging of tuberculous meningitis is based on neurologic status, as follows:  Stage 1 - No change in mental function, with no deficits and no hydrocephalus  Stage 2 - Confusion and evidence of neurologic deficit  Stage 3 - Stupor and lethargy T U B E R C U L O U S M E N I N G I T I S C L I N I C A L S TA G I N G O F T U B E R C U L O U S M E N I N G I T I S
  • 35. NEISSERIA MENINGITIDIS COMPLICATIONS 1 . H E A R I N G L O S S 2 . C E R E B R A L O E D E M A A N D I N C R E A S E D I C P 4 . B R A I N A B S C E S S 4 . S T R O K E Infections / inflammation from subarachnoid space  via cochlear aqueduct  inner ear  Inflammatory response – damages cochlear (hair cells) Cerebral edema may be vasogenic, from increased vascular permeability, cytotoxic from cerebral hypoxia, interstitial, from increased CSF volume, or a combination of all. Increased intracranial pressure, in turn, causes decreased cerebral perfusion, hypoxia/ischemia, and neuronal necrosis. 3 . D I S S E M I N AT E D I N T R A V A S C U L A R C O A G U L O PAT H Y ( D I C ) Bacterial products can damage the brain and blood vessels directly. Bacterial toxins cause neuronal apoptosis, and cell wall lipopolysaccharide (endotoxin), released from bacteria, activates clotting causing disseminated intravascular coagulation (DIC).
  • 36. NEISSERIA MENINGITIDIS DIFFERENTIAL DIAGNOSIS 1 . S u b a r a c h n o i d h e m o r r h a g e 2 . T B m e n i n g i t i s 3 . S p a c e - o c c u p y i n g l e s i o n 4 . M e n i n g o e n c a p h a l i t i s 5 . E p i l e p s y
  • 37. NEISSERIA MENINGITIDIS INVESTIGATIONS B L O O D T E S T S 1. Full blood count ( white cell count) 2. C-reactive protein 3. Blood culture and sensitivity L U M B A R P U N C T U R E A N D C S F A N A LY S I S For definitive diagnosis of meningitis, CSF needs to be collected for analysis. C O N T R A I N D I C AT I O N S  Infected skin over needle entry site  Suspicion of increase ICP  Coagulopathy  Significant cardiorespiratory compromise  Immunocompromised
  • 38. NEISSERIA MENINGITIDIS INVESTIGATIONS L U M B A R P U N C T U R E A N D C S F A N A LY S I S T E S T B A C T E R I A L V I R A L F U N G A L T U B E R C U L A R Opening pressure Elevated Normal Variable Variable WBC count >1,000 / mm3 <100/mm3 Variable Variable Cell differential Neutrophils Lymphocytes Lymphocytes Lymphocytes Protein Mild to marked elevation Normal or mildly elevated Elevated Very high CSF-to-serum glucose ratio Markedly decreased normal Low Low I M A G I N G If a patient has the following: Focal neurologic findings (excluding cranial nerve palsies), new-onset seizures, severely immunocompromised state, papilledema or presents with coma, perform a head computed tomography scan prior to doing a lumbar puncture to rule out the presence of intracranial mass lesions because of the potential risk for herniation
  • 39. NEISSERIA MENINGITIDIS MANAGEMENT S U P P O R T I V E T R E AT M E N T Airway, breathing and circulation  Mechanical ventilation – level of consciousness is very low / evidence of respiratory failure  Intravenous fluid therapy – if hypotension or shock are present Monitor vital signs and neurologic status regularly Maintain adequate hydration and nutrition – tube feeding may be necessary D E F I N I T I V E T R E AT M E N T ( P H A R M A C O T H E R PA P Y ) 1. Antibiotic therapy 2. Anti-inflammatory therapy 3. Agents to decrease intracranial pressure (ICP) 4. Anti-convulsants
  • 40. NEISSERIA MENINGITIDIS MANAGEMENT A N T I B I O T I C S ( A C U T E M E N I N G I T I S ) I N F E C T I O N S U G G E S T E D T R E A T M E N T C O M M E N T S P R E F E R R E D A L T E R N A T I V E Common organisms:  Streptococcus pneumoniae  Neisseria meningitidis  Haemophilus influenzae Ceftriaxone 2gm IV q12h OR Cefotaxime 2 – 4gm IV q8h Dexamethasone 10mg IV q6h is recommended to be administered 15 to 20 minutes before or at the time of first dose of antibiotics, for up to 4 days or until there is no evidence of pneumococcal meningitis. Antibiotic treatment must be started immediately, regardless of any investigations undertaken. If no organism isolated and patient is responding, continue antibiotics for 14 days.
  • 41. NEISSERIA MENINGITIDIS MANAGEMENT A N T I B I O T I C S ( A C U T E M E N I N G I T I S ) I S O L A T E D C A U S A T I V E O R G A N I S M S U G G E S T E D T R E A T M E N T C O M M E N T S P R E F E R R E D A L T E R N A T I V E HAEMOPHILUS INFUENZAE (GRAM –VE BACILLI) Ceftriaxone 2gm IV q12h STREPTOCOCCUS PNEUMONIAE (GRAM +VE COCCI) Benzylpenicillin 4MU IV q4- 6h for 10-14 days. For penicillin resistant strains Vancomycin 1gm IV q12h NEISSERIA MENINGITIDIS (GRAM –VE COCCI) Prophylaxis for household and close contact of meningococcal meningitis Ceftriaxone 2gm IV q12h Ciprofloxacin 500mg PO as single dose; Close contacts are defined as those individuals who have had contact with oropharyngeal secretions either through kissing or by sharing toys, beverages, or cigarettes.
  • 42. NEISSERIA MENINGITIDIS MANAGEMENT A N T I B I O T I C S ( C H R O N I C M E N I N G I T I S ) I N F E C T I O N S U G G E S T E D T R E A T M E N T C O M M E N T S P R E F E R R E D A L T E R N A T I V E TUBERCULOUS MENINGITIS Mycobacterium tuberculosis Intensive 2 months S/EHRZ and 10 months HR Pyridoxine 10- 50mg PO q24h needs to be prescribed together with Isoniazid. (Streptomycin should replace Ethambutol in TB meningitis as it crosses BBB better than Ethambutol.) Treatment is continued for 12 months. CPG on management of Tuberculosis, 3rd edition, 2012; 16, 22, 40-42, 56) WHO Treatment of Tuberculosis Guidelines, 4th ed. 2009
  • 43. NEISSERIA MENINGITIDIS MANAGEMENT A N T I - I N F L A M M AT O R Y T H E R A P Y Dexamethasone 10 mg IV 6 hourly x 4 days Mannitol 1 – 1.5 g/kg IV given over 15 minutes I C P L O W E R I N G A G E N T A N T I C O N V U L S A N T S Diazepam, Lorazepam Administered if patient has seizure Action: Mannitol is a hyperosmolar agent that makes the intravascular space hyperosmolar to the brain and permits movement of water from brain tissue into the intravascular compartment
  • 44. NEISSERIA MENINGITIDIS PREVENTION AND PROPHYLAXIS P R E C A U T I O N Completion of recommended schedule of vaccination is an effective way of protecting individuals from certain types of bacterial meningitis (E.g. meningococcus, pneumococcus and Hib) F O L L O W U P  Repeat cerebrospinal fluid exam in patients in whom there is doubt about the success of therapy or the accuracy of the initial diagnosis  Patients who respond promptly to therapy may no longer need repeat cerebrospinal fluid exams  Monitor for hydrocephalus and treat the condition appropriately - hydrocephalus usually manifests within the first few weeks of infection and is treated with ventriculoperitoneal shunting  Monitor for neurologic sequelae and provide appropriate supportive therapy  Sequelae include hearing impairment, cranial nerve palsies and motor deficits  Supportive therapy should be individually tailored Use of mask, gloves, and gowns prevents spread of disease as meningitis is a droplet infection V A C C I N AT I O N